Scarica l'app Stockscreener
56.86
0.11%
0.06
Precedente Chiudi:
$56.80
Aprire:
$56.8
Volume 24 ore:
1.80M
Relative Volume:
0.79
Capitalizzazione di mercato:
$10.92B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
21.14
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-8.19%
1M Prestazione:
-2.13%
6M Prestazione:
-13.67%
1 anno Prestazione:
-36.13%
Intervallo 1D:
$56.45
$57.46
Intervallo di 1 settimana:
$56.36
$61.75
Portata 52W:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
56.86 | 10.91B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - uk.finance.yahoo.com
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - Yahoo Finance
Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals
BioMarin Announces Resignation of Chief Accounting Officer - TipRanks
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - inkl
BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
BMRN Makes Bullish Cross Above Critical Moving Average - Nasdaq
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating - MarketScreener
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View - Yahoo Finance
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating - MarketScreener
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin: Q2 Earnings Snapshot - New Haven Register
BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin’s Earnings Beat Forecasts And Hike Guidance For 2025 - Finimize
BioMarin Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
BioMarin (BMRN) Q2 Revenue Jumps 16% - The Motley Fool
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises - Investing.com
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioMarin Pharmaceutical Reports Strong Q2 EarningsNews and Statistics - IndexBox
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars - TradingView
BioMarin Pharmaceutical Q2 Non-GAAP EPS, Revenue Increase; Shares Rise After Hours - MarketScreener
BioMarin Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q2 Revenue $825.0M, vs. FactSet Est of $761.7M - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.44 per Share, vs. FactSet Est of $0.82 - MarketScreener
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS - PR Newswire
What makes BioMarin Pharmaceutical Inc. stock price move sharplyGet real-time alerts on top-performing stocks - Jammu Links News
How does BioMarin Pharmaceutical Inc. compare to its industry peersBuild a portfolio that grows with the market - Jammu Links News
Is BioMarin Pharmaceutical Inc. a good long term investmentCapitalize on emerging industry trends - Jammu Links News
How volatile is BioMarin Pharmaceutical Inc. stock compared to the marketHigh-octane gains - Jammu Links News
What is the dividend policy of BioMarin Pharmaceutical Inc. stockSuperior trading gains - Jammu Links News
BioMarin Pharmaceuticals Appoints Ian T. Clark to Board of Directors - AInvest
When is BioMarin Pharmaceutical Inc. stock expected to show significant growthBuild capital through low-risk investments - Jammu Links News
What is BioMarin Pharmaceutical Inc. company’s growth strategySky-high profits - Jammu Links News
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):